LANCET ONCOL 润色咨询

LANCET ONCOLOGY

出版年份:2000 年文章数:1511 投稿命中率: 开通期刊会员,数据随心看

出版周期:Monthly 自引率:1.7% 审稿周期: 开通期刊会员,数据随心看

前往期刊查询

期刊讨论

  1. [GetPortalCommentsPageByObjectIdResponse(id=2139420, encodeId=97e021394204a, content=投稿投稿,天天发愁, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=192, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ede62857934, createdName=4031828, createdTime=Sat May 27 21:18:24 CST 2023, time=2023-05-27, status=1, ipAttribution=河南省), GetPortalCommentsPageByObjectIdResponse(id=2145327, encodeId=58e0214532e67, content=影响因子51.1分,顶刊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=167, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/Random/55971dc507c93968175ce7cc1e177b372a83869f.jpg, createdBy=f63e4754896, createdName=侠胆医心, createdTime=Thu Jun 29 05:35:33 CST 2023, time=2023-06-29, status=1, ipAttribution=香港), GetPortalCommentsPageByObjectIdResponse(id=504738, encodeId=4b54504e380c, content=审稿速度:1.0 | 投稿命中率:25.0<br>经验分享:楼上投稿,秒拒,可能是研究根本不合适。Lancet Oncology,国内发得多了,吴一龙教授,周彩纯教授,滕皋军教授,他们发了好多,尤其是吴一龙教授和周彩纯教授,几乎成为Lancet Oncology专业户了。一般来说,首先是RCT,但是可以是小规模的(即phase 2),这是可以的。另外,研究应该是很新的话题,如NSCLC,前几年研究EGFR突变,现在呢,一定要做ALK或ROS1之类,另外,研究的传承至关重要,因为发表前,都要附一个system review才可以,你要说明,为什么要开展这个研究,而不是无缘无故做的。我知道medsci协助国内好多大牛发了这个刊物。只要研究合适,似乎并不是这么恐怖的刊物。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=960, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=丁丁, createdTime=Wed Jul 30 18:11:00 CST 2014, time=2014-07-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=579996, encodeId=04305e99960d, content=接受回顾性队列研究吗?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=673, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f0fb2030145, createdName=1e2321c7m65(暂无匿称), createdTime=Sun Nov 17 00:00:00 CST 2019, time=2019-11-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1098625, encodeId=c09310986258e, content=我为什么投了一个月/很长时间都没有消息?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=477, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220301/3a52d3952dde49019f1e000bb5c41d1c/0a0eb7959bb14fcd87745f869bee3c33.jpg, createdBy=46f32239729, createdName=Mia, createdTime=Wed Dec 29 14:52:50 CST 2021, time=2021-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1098626, encodeId=39cd1098626af, content=期刊的审稿时间一般是多久?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=474, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210512/72cbdf927f7647bd84938927488b4795/94fe7f0fd8274d94807c5f3458f0c4e2.jpg, createdBy=9cd75497899, createdName=桑晒麦拉, createdTime=Tue Dec 28 14:52:50 CST 2021, time=2021-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=586501, encodeId=5c2f586501a5, content=最多几个共一啊<span class="quote">lovetcm 2019-06-21 00:00:00 发表:<br>周大大经常发这个期刊</span>, beContent=lovetcm 2019-06-21 00:00:00 发表: 周大大经常发这个期刊, objectType=tool_impact_factor, channel=null, level=null, likeNumber=649, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTKGbxgDxjD7wnYeUQoH0hkCdFqbfXdHY0UL0jBF5ar37Qgo4oA3a9xcLBeadTqricpicm1H9XUJkfnQ/132, createdBy=26d52133758, createdName=陈晓晓晓, createdTime=Fri Mar 13 00:00:00 CST 2020, time=2020-03-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=572694, encodeId=3b7b5e269478, content=周大大经常发这个期刊<span class="quote">153****5167(暂无匿称) 2017-02-02 发表::<br>研究方向:肿瘤;癌症; SCI(2015):26.509 SCI(2014):24.69 是周彩存</span><span class="quote">153****5167(暂无匿称) 2017-02-02 14:14:00 发表:<br>是周彩存</span>, beContent=153****5167(暂无匿称) 2017-02-02 发表:: 研究方向:肿瘤;癌症; SCI(2015):26.509 SCI(2014):24.69 是周彩存, objectType=tool_impact_factor, channel=null, level=null, likeNumber=707, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c4a5105539, createdName=lovetcm, createdTime=Fri Jun 21 00:00:00 CST 2019, time=2019-06-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=572619, encodeId=7bfb5e261999, content=转化研究收的都少,纯基础不收。<span class="quote">sunliang 2019-01-01 发表::<br>这个杂志收基础的文章吗?</span><span class="quote">sunliang 2019-01-01 00:00:00 发表:<br>这个杂志收基础的文章吗?</span>, beContent=sunliang 2019-01-01 发表:: 这个杂志收基础的文章吗?, objectType=tool_impact_factor, channel=null, level=null, likeNumber=750, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c4a5105539, createdName=lovetcm, createdTime=Fri Jun 21 00:00:00 CST 2019, time=2019-06-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=565790, encodeId=c65f565e90f1, content=同学,这个杂志投稿要求能分析一个吗?特别是作者填写,字体大小格式的要求我都找到了<span class="quote">henrypoor 2014-07-30 17:57:00 发表:<br>今天投了一篇,要么就秒拒,要不就赶紧送外审了吧,跪求!!!求祝福!</span>, beContent=henrypoor 2014-07-30 17:57:00 发表: 今天投了一篇,要么就秒拒,要不就赶紧送外审了吧,跪求!!!求祝福!, objectType=tool_impact_factor, channel=null, level=null, likeNumber=742, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/DYAIOgq83eq1fibWvf6gzfzbEVuEZtllrHnhxFxdCXjODby1mSKU0CWzYgFUjtZuufiaSV4ub9l0Ixjjb56SWiaicg/132, createdBy=5e3a2395315, createdName=助手我老婆, createdTime=Sun Jan 20 00:00:00 CST 2019, time=2019-01-20, status=1, ipAttribution=)]
    2023-05-27 4031828 来自河南省

    投稿投稿,天天发愁

    1

    展开1条回复
  2. [GetPortalCommentsPageByObjectIdResponse(id=2139420, encodeId=97e021394204a, content=投稿投稿,天天发愁, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=192, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ede62857934, createdName=4031828, createdTime=Sat May 27 21:18:24 CST 2023, time=2023-05-27, status=1, ipAttribution=河南省), GetPortalCommentsPageByObjectIdResponse(id=2145327, encodeId=58e0214532e67, content=影响因子51.1分,顶刊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=167, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/Random/55971dc507c93968175ce7cc1e177b372a83869f.jpg, createdBy=f63e4754896, createdName=侠胆医心, createdTime=Thu Jun 29 05:35:33 CST 2023, time=2023-06-29, status=1, ipAttribution=香港), GetPortalCommentsPageByObjectIdResponse(id=504738, encodeId=4b54504e380c, content=审稿速度:1.0 | 投稿命中率:25.0<br>经验分享:楼上投稿,秒拒,可能是研究根本不合适。Lancet Oncology,国内发得多了,吴一龙教授,周彩纯教授,滕皋军教授,他们发了好多,尤其是吴一龙教授和周彩纯教授,几乎成为Lancet Oncology专业户了。一般来说,首先是RCT,但是可以是小规模的(即phase 2),这是可以的。另外,研究应该是很新的话题,如NSCLC,前几年研究EGFR突变,现在呢,一定要做ALK或ROS1之类,另外,研究的传承至关重要,因为发表前,都要附一个system review才可以,你要说明,为什么要开展这个研究,而不是无缘无故做的。我知道medsci协助国内好多大牛发了这个刊物。只要研究合适,似乎并不是这么恐怖的刊物。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=960, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=丁丁, createdTime=Wed Jul 30 18:11:00 CST 2014, time=2014-07-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=579996, encodeId=04305e99960d, content=接受回顾性队列研究吗?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=673, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f0fb2030145, createdName=1e2321c7m65(暂无匿称), createdTime=Sun Nov 17 00:00:00 CST 2019, time=2019-11-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1098625, encodeId=c09310986258e, content=我为什么投了一个月/很长时间都没有消息?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=477, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220301/3a52d3952dde49019f1e000bb5c41d1c/0a0eb7959bb14fcd87745f869bee3c33.jpg, createdBy=46f32239729, createdName=Mia, createdTime=Wed Dec 29 14:52:50 CST 2021, time=2021-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1098626, encodeId=39cd1098626af, content=期刊的审稿时间一般是多久?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=474, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210512/72cbdf927f7647bd84938927488b4795/94fe7f0fd8274d94807c5f3458f0c4e2.jpg, createdBy=9cd75497899, createdName=桑晒麦拉, createdTime=Tue Dec 28 14:52:50 CST 2021, time=2021-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=586501, encodeId=5c2f586501a5, content=最多几个共一啊<span class="quote">lovetcm 2019-06-21 00:00:00 发表:<br>周大大经常发这个期刊</span>, beContent=lovetcm 2019-06-21 00:00:00 发表: 周大大经常发这个期刊, objectType=tool_impact_factor, channel=null, level=null, likeNumber=649, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTKGbxgDxjD7wnYeUQoH0hkCdFqbfXdHY0UL0jBF5ar37Qgo4oA3a9xcLBeadTqricpicm1H9XUJkfnQ/132, createdBy=26d52133758, createdName=陈晓晓晓, createdTime=Fri Mar 13 00:00:00 CST 2020, time=2020-03-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=572694, encodeId=3b7b5e269478, content=周大大经常发这个期刊<span class="quote">153****5167(暂无匿称) 2017-02-02 发表::<br>研究方向:肿瘤;癌症; SCI(2015):26.509 SCI(2014):24.69 是周彩存</span><span class="quote">153****5167(暂无匿称) 2017-02-02 14:14:00 发表:<br>是周彩存</span>, beContent=153****5167(暂无匿称) 2017-02-02 发表:: 研究方向:肿瘤;癌症; SCI(2015):26.509 SCI(2014):24.69 是周彩存, objectType=tool_impact_factor, channel=null, level=null, likeNumber=707, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c4a5105539, createdName=lovetcm, createdTime=Fri Jun 21 00:00:00 CST 2019, time=2019-06-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=572619, encodeId=7bfb5e261999, content=转化研究收的都少,纯基础不收。<span class="quote">sunliang 2019-01-01 发表::<br>这个杂志收基础的文章吗?</span><span class="quote">sunliang 2019-01-01 00:00:00 发表:<br>这个杂志收基础的文章吗?</span>, beContent=sunliang 2019-01-01 发表:: 这个杂志收基础的文章吗?, objectType=tool_impact_factor, channel=null, level=null, likeNumber=750, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c4a5105539, createdName=lovetcm, createdTime=Fri Jun 21 00:00:00 CST 2019, time=2019-06-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=565790, encodeId=c65f565e90f1, content=同学,这个杂志投稿要求能分析一个吗?特别是作者填写,字体大小格式的要求我都找到了<span class="quote">henrypoor 2014-07-30 17:57:00 发表:<br>今天投了一篇,要么就秒拒,要不就赶紧送外审了吧,跪求!!!求祝福!</span>, beContent=henrypoor 2014-07-30 17:57:00 发表: 今天投了一篇,要么就秒拒,要不就赶紧送外审了吧,跪求!!!求祝福!, objectType=tool_impact_factor, channel=null, level=null, likeNumber=742, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/DYAIOgq83eq1fibWvf6gzfzbEVuEZtllrHnhxFxdCXjODby1mSKU0CWzYgFUjtZuufiaSV4ub9l0Ixjjb56SWiaicg/132, createdBy=5e3a2395315, createdName=助手我老婆, createdTime=Sun Jan 20 00:00:00 CST 2019, time=2019-01-20, status=1, ipAttribution=)]
    2023-06-29 侠胆医心 来自香港

    影响因子51.1分,顶刊

    1

    展开1条回复
  3. [GetPortalCommentsPageByObjectIdResponse(id=2139420, encodeId=97e021394204a, content=投稿投稿,天天发愁, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=192, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ede62857934, createdName=4031828, createdTime=Sat May 27 21:18:24 CST 2023, time=2023-05-27, status=1, ipAttribution=河南省), GetPortalCommentsPageByObjectIdResponse(id=2145327, encodeId=58e0214532e67, content=影响因子51.1分,顶刊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=167, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/Random/55971dc507c93968175ce7cc1e177b372a83869f.jpg, createdBy=f63e4754896, createdName=侠胆医心, createdTime=Thu Jun 29 05:35:33 CST 2023, time=2023-06-29, status=1, ipAttribution=香港), GetPortalCommentsPageByObjectIdResponse(id=504738, encodeId=4b54504e380c, content=审稿速度:1.0 | 投稿命中率:25.0<br>经验分享:楼上投稿,秒拒,可能是研究根本不合适。Lancet Oncology,国内发得多了,吴一龙教授,周彩纯教授,滕皋军教授,他们发了好多,尤其是吴一龙教授和周彩纯教授,几乎成为Lancet Oncology专业户了。一般来说,首先是RCT,但是可以是小规模的(即phase 2),这是可以的。另外,研究应该是很新的话题,如NSCLC,前几年研究EGFR突变,现在呢,一定要做ALK或ROS1之类,另外,研究的传承至关重要,因为发表前,都要附一个system review才可以,你要说明,为什么要开展这个研究,而不是无缘无故做的。我知道medsci协助国内好多大牛发了这个刊物。只要研究合适,似乎并不是这么恐怖的刊物。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=960, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=丁丁, createdTime=Wed Jul 30 18:11:00 CST 2014, time=2014-07-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=579996, encodeId=04305e99960d, content=接受回顾性队列研究吗?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=673, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f0fb2030145, createdName=1e2321c7m65(暂无匿称), createdTime=Sun Nov 17 00:00:00 CST 2019, time=2019-11-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1098625, encodeId=c09310986258e, content=我为什么投了一个月/很长时间都没有消息?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=477, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220301/3a52d3952dde49019f1e000bb5c41d1c/0a0eb7959bb14fcd87745f869bee3c33.jpg, createdBy=46f32239729, createdName=Mia, createdTime=Wed Dec 29 14:52:50 CST 2021, time=2021-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1098626, encodeId=39cd1098626af, content=期刊的审稿时间一般是多久?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=474, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210512/72cbdf927f7647bd84938927488b4795/94fe7f0fd8274d94807c5f3458f0c4e2.jpg, createdBy=9cd75497899, createdName=桑晒麦拉, createdTime=Tue Dec 28 14:52:50 CST 2021, time=2021-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=586501, encodeId=5c2f586501a5, content=最多几个共一啊<span class="quote">lovetcm 2019-06-21 00:00:00 发表:<br>周大大经常发这个期刊</span>, beContent=lovetcm 2019-06-21 00:00:00 发表: 周大大经常发这个期刊, objectType=tool_impact_factor, channel=null, level=null, likeNumber=649, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTKGbxgDxjD7wnYeUQoH0hkCdFqbfXdHY0UL0jBF5ar37Qgo4oA3a9xcLBeadTqricpicm1H9XUJkfnQ/132, createdBy=26d52133758, createdName=陈晓晓晓, createdTime=Fri Mar 13 00:00:00 CST 2020, time=2020-03-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=572694, encodeId=3b7b5e269478, content=周大大经常发这个期刊<span class="quote">153****5167(暂无匿称) 2017-02-02 发表::<br>研究方向:肿瘤;癌症; SCI(2015):26.509 SCI(2014):24.69 是周彩存</span><span class="quote">153****5167(暂无匿称) 2017-02-02 14:14:00 发表:<br>是周彩存</span>, beContent=153****5167(暂无匿称) 2017-02-02 发表:: 研究方向:肿瘤;癌症; SCI(2015):26.509 SCI(2014):24.69 是周彩存, objectType=tool_impact_factor, channel=null, level=null, likeNumber=707, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c4a5105539, createdName=lovetcm, createdTime=Fri Jun 21 00:00:00 CST 2019, time=2019-06-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=572619, encodeId=7bfb5e261999, content=转化研究收的都少,纯基础不收。<span class="quote">sunliang 2019-01-01 发表::<br>这个杂志收基础的文章吗?</span><span class="quote">sunliang 2019-01-01 00:00:00 发表:<br>这个杂志收基础的文章吗?</span>, beContent=sunliang 2019-01-01 发表:: 这个杂志收基础的文章吗?, objectType=tool_impact_factor, channel=null, level=null, likeNumber=750, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c4a5105539, createdName=lovetcm, createdTime=Fri Jun 21 00:00:00 CST 2019, time=2019-06-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=565790, encodeId=c65f565e90f1, content=同学,这个杂志投稿要求能分析一个吗?特别是作者填写,字体大小格式的要求我都找到了<span class="quote">henrypoor 2014-07-30 17:57:00 发表:<br>今天投了一篇,要么就秒拒,要不就赶紧送外审了吧,跪求!!!求祝福!</span>, beContent=henrypoor 2014-07-30 17:57:00 发表: 今天投了一篇,要么就秒拒,要不就赶紧送外审了吧,跪求!!!求祝福!, objectType=tool_impact_factor, channel=null, level=null, likeNumber=742, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/DYAIOgq83eq1fibWvf6gzfzbEVuEZtllrHnhxFxdCXjODby1mSKU0CWzYgFUjtZuufiaSV4ub9l0Ixjjb56SWiaicg/132, createdBy=5e3a2395315, createdName=助手我老婆, createdTime=Sun Jan 20 00:00:00 CST 2019, time=2019-01-20, status=1, ipAttribution=)]
    2014-07-30 丁丁

    审稿速度:1.0 | 投稿命中率:25.0
    经验分享:楼上投稿,秒拒,可能是研究根本不合适。Lancet Oncology,国内发得多了,吴一龙教授,周彩纯教授,滕皋军教授,他们发了好多,尤其是吴一龙教授和周彩纯教授,几乎成为Lancet Oncology专业户了。一般来说,首先是RCT,但是可以是小规模的(即phase 2),这是可以的。另外,研究应该是很新的话题,如NSCLC,前几年研究EGFR突变,现在呢,一定要做ALK或ROS1之类,另外,研究的传承至关重要,因为发表前,都要附一个system review才可以,你要说明,为什么要开展这个研究,而不是无缘无故做的。我知道medsci协助国内好多大牛发了这个刊物。只要研究合适,似乎并不是这么恐怖的刊物。

    5

    展开5条回复
  4. [GetPortalCommentsPageByObjectIdResponse(id=2139420, encodeId=97e021394204a, content=投稿投稿,天天发愁, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=192, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ede62857934, createdName=4031828, createdTime=Sat May 27 21:18:24 CST 2023, time=2023-05-27, status=1, ipAttribution=河南省), GetPortalCommentsPageByObjectIdResponse(id=2145327, encodeId=58e0214532e67, content=影响因子51.1分,顶刊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=167, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/Random/55971dc507c93968175ce7cc1e177b372a83869f.jpg, createdBy=f63e4754896, createdName=侠胆医心, createdTime=Thu Jun 29 05:35:33 CST 2023, time=2023-06-29, status=1, ipAttribution=香港), GetPortalCommentsPageByObjectIdResponse(id=504738, encodeId=4b54504e380c, content=审稿速度:1.0 | 投稿命中率:25.0<br>经验分享:楼上投稿,秒拒,可能是研究根本不合适。Lancet Oncology,国内发得多了,吴一龙教授,周彩纯教授,滕皋军教授,他们发了好多,尤其是吴一龙教授和周彩纯教授,几乎成为Lancet Oncology专业户了。一般来说,首先是RCT,但是可以是小规模的(即phase 2),这是可以的。另外,研究应该是很新的话题,如NSCLC,前几年研究EGFR突变,现在呢,一定要做ALK或ROS1之类,另外,研究的传承至关重要,因为发表前,都要附一个system review才可以,你要说明,为什么要开展这个研究,而不是无缘无故做的。我知道medsci协助国内好多大牛发了这个刊物。只要研究合适,似乎并不是这么恐怖的刊物。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=960, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=丁丁, createdTime=Wed Jul 30 18:11:00 CST 2014, time=2014-07-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=579996, encodeId=04305e99960d, content=接受回顾性队列研究吗?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=673, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f0fb2030145, createdName=1e2321c7m65(暂无匿称), createdTime=Sun Nov 17 00:00:00 CST 2019, time=2019-11-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1098625, encodeId=c09310986258e, content=我为什么投了一个月/很长时间都没有消息?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=477, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220301/3a52d3952dde49019f1e000bb5c41d1c/0a0eb7959bb14fcd87745f869bee3c33.jpg, createdBy=46f32239729, createdName=Mia, createdTime=Wed Dec 29 14:52:50 CST 2021, time=2021-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1098626, encodeId=39cd1098626af, content=期刊的审稿时间一般是多久?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=474, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210512/72cbdf927f7647bd84938927488b4795/94fe7f0fd8274d94807c5f3458f0c4e2.jpg, createdBy=9cd75497899, createdName=桑晒麦拉, createdTime=Tue Dec 28 14:52:50 CST 2021, time=2021-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=586501, encodeId=5c2f586501a5, content=最多几个共一啊<span class="quote">lovetcm 2019-06-21 00:00:00 发表:<br>周大大经常发这个期刊</span>, beContent=lovetcm 2019-06-21 00:00:00 发表: 周大大经常发这个期刊, objectType=tool_impact_factor, channel=null, level=null, likeNumber=649, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTKGbxgDxjD7wnYeUQoH0hkCdFqbfXdHY0UL0jBF5ar37Qgo4oA3a9xcLBeadTqricpicm1H9XUJkfnQ/132, createdBy=26d52133758, createdName=陈晓晓晓, createdTime=Fri Mar 13 00:00:00 CST 2020, time=2020-03-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=572694, encodeId=3b7b5e269478, content=周大大经常发这个期刊<span class="quote">153****5167(暂无匿称) 2017-02-02 发表::<br>研究方向:肿瘤;癌症; SCI(2015):26.509 SCI(2014):24.69 是周彩存</span><span class="quote">153****5167(暂无匿称) 2017-02-02 14:14:00 发表:<br>是周彩存</span>, beContent=153****5167(暂无匿称) 2017-02-02 发表:: 研究方向:肿瘤;癌症; SCI(2015):26.509 SCI(2014):24.69 是周彩存, objectType=tool_impact_factor, channel=null, level=null, likeNumber=707, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c4a5105539, createdName=lovetcm, createdTime=Fri Jun 21 00:00:00 CST 2019, time=2019-06-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=572619, encodeId=7bfb5e261999, content=转化研究收的都少,纯基础不收。<span class="quote">sunliang 2019-01-01 发表::<br>这个杂志收基础的文章吗?</span><span class="quote">sunliang 2019-01-01 00:00:00 发表:<br>这个杂志收基础的文章吗?</span>, beContent=sunliang 2019-01-01 发表:: 这个杂志收基础的文章吗?, objectType=tool_impact_factor, channel=null, level=null, likeNumber=750, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c4a5105539, createdName=lovetcm, createdTime=Fri Jun 21 00:00:00 CST 2019, time=2019-06-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=565790, encodeId=c65f565e90f1, content=同学,这个杂志投稿要求能分析一个吗?特别是作者填写,字体大小格式的要求我都找到了<span class="quote">henrypoor 2014-07-30 17:57:00 发表:<br>今天投了一篇,要么就秒拒,要不就赶紧送外审了吧,跪求!!!求祝福!</span>, beContent=henrypoor 2014-07-30 17:57:00 发表: 今天投了一篇,要么就秒拒,要不就赶紧送外审了吧,跪求!!!求祝福!, objectType=tool_impact_factor, channel=null, level=null, likeNumber=742, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/DYAIOgq83eq1fibWvf6gzfzbEVuEZtllrHnhxFxdCXjODby1mSKU0CWzYgFUjtZuufiaSV4ub9l0Ixjjb56SWiaicg/132, createdBy=5e3a2395315, createdName=助手我老婆, createdTime=Sun Jan 20 00:00:00 CST 2019, time=2019-01-20, status=1, ipAttribution=)]
    2019-11-17 1e2321c7m65(暂无匿称)

    接受回顾性队列研究吗?

    2

    展开2条回复
  5. [GetPortalCommentsPageByObjectIdResponse(id=2139420, encodeId=97e021394204a, content=投稿投稿,天天发愁, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=192, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ede62857934, createdName=4031828, createdTime=Sat May 27 21:18:24 CST 2023, time=2023-05-27, status=1, ipAttribution=河南省), GetPortalCommentsPageByObjectIdResponse(id=2145327, encodeId=58e0214532e67, content=影响因子51.1分,顶刊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=167, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/Random/55971dc507c93968175ce7cc1e177b372a83869f.jpg, createdBy=f63e4754896, createdName=侠胆医心, createdTime=Thu Jun 29 05:35:33 CST 2023, time=2023-06-29, status=1, ipAttribution=香港), GetPortalCommentsPageByObjectIdResponse(id=504738, encodeId=4b54504e380c, content=审稿速度:1.0 | 投稿命中率:25.0<br>经验分享:楼上投稿,秒拒,可能是研究根本不合适。Lancet Oncology,国内发得多了,吴一龙教授,周彩纯教授,滕皋军教授,他们发了好多,尤其是吴一龙教授和周彩纯教授,几乎成为Lancet Oncology专业户了。一般来说,首先是RCT,但是可以是小规模的(即phase 2),这是可以的。另外,研究应该是很新的话题,如NSCLC,前几年研究EGFR突变,现在呢,一定要做ALK或ROS1之类,另外,研究的传承至关重要,因为发表前,都要附一个system review才可以,你要说明,为什么要开展这个研究,而不是无缘无故做的。我知道medsci协助国内好多大牛发了这个刊物。只要研究合适,似乎并不是这么恐怖的刊物。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=960, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=丁丁, createdTime=Wed Jul 30 18:11:00 CST 2014, time=2014-07-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=579996, encodeId=04305e99960d, content=接受回顾性队列研究吗?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=673, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f0fb2030145, createdName=1e2321c7m65(暂无匿称), createdTime=Sun Nov 17 00:00:00 CST 2019, time=2019-11-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1098625, encodeId=c09310986258e, content=我为什么投了一个月/很长时间都没有消息?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=477, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220301/3a52d3952dde49019f1e000bb5c41d1c/0a0eb7959bb14fcd87745f869bee3c33.jpg, createdBy=46f32239729, createdName=Mia, createdTime=Wed Dec 29 14:52:50 CST 2021, time=2021-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1098626, encodeId=39cd1098626af, content=期刊的审稿时间一般是多久?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=474, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210512/72cbdf927f7647bd84938927488b4795/94fe7f0fd8274d94807c5f3458f0c4e2.jpg, createdBy=9cd75497899, createdName=桑晒麦拉, createdTime=Tue Dec 28 14:52:50 CST 2021, time=2021-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=586501, encodeId=5c2f586501a5, content=最多几个共一啊<span class="quote">lovetcm 2019-06-21 00:00:00 发表:<br>周大大经常发这个期刊</span>, beContent=lovetcm 2019-06-21 00:00:00 发表: 周大大经常发这个期刊, objectType=tool_impact_factor, channel=null, level=null, likeNumber=649, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTKGbxgDxjD7wnYeUQoH0hkCdFqbfXdHY0UL0jBF5ar37Qgo4oA3a9xcLBeadTqricpicm1H9XUJkfnQ/132, createdBy=26d52133758, createdName=陈晓晓晓, createdTime=Fri Mar 13 00:00:00 CST 2020, time=2020-03-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=572694, encodeId=3b7b5e269478, content=周大大经常发这个期刊<span class="quote">153****5167(暂无匿称) 2017-02-02 发表::<br>研究方向:肿瘤;癌症; SCI(2015):26.509 SCI(2014):24.69 是周彩存</span><span class="quote">153****5167(暂无匿称) 2017-02-02 14:14:00 发表:<br>是周彩存</span>, beContent=153****5167(暂无匿称) 2017-02-02 发表:: 研究方向:肿瘤;癌症; SCI(2015):26.509 SCI(2014):24.69 是周彩存, objectType=tool_impact_factor, channel=null, level=null, likeNumber=707, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c4a5105539, createdName=lovetcm, createdTime=Fri Jun 21 00:00:00 CST 2019, time=2019-06-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=572619, encodeId=7bfb5e261999, content=转化研究收的都少,纯基础不收。<span class="quote">sunliang 2019-01-01 发表::<br>这个杂志收基础的文章吗?</span><span class="quote">sunliang 2019-01-01 00:00:00 发表:<br>这个杂志收基础的文章吗?</span>, beContent=sunliang 2019-01-01 发表:: 这个杂志收基础的文章吗?, objectType=tool_impact_factor, channel=null, level=null, likeNumber=750, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c4a5105539, createdName=lovetcm, createdTime=Fri Jun 21 00:00:00 CST 2019, time=2019-06-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=565790, encodeId=c65f565e90f1, content=同学,这个杂志投稿要求能分析一个吗?特别是作者填写,字体大小格式的要求我都找到了<span class="quote">henrypoor 2014-07-30 17:57:00 发表:<br>今天投了一篇,要么就秒拒,要不就赶紧送外审了吧,跪求!!!求祝福!</span>, beContent=henrypoor 2014-07-30 17:57:00 发表: 今天投了一篇,要么就秒拒,要不就赶紧送外审了吧,跪求!!!求祝福!, objectType=tool_impact_factor, channel=null, level=null, likeNumber=742, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/DYAIOgq83eq1fibWvf6gzfzbEVuEZtllrHnhxFxdCXjODby1mSKU0CWzYgFUjtZuufiaSV4ub9l0Ixjjb56SWiaicg/132, createdBy=5e3a2395315, createdName=助手我老婆, createdTime=Sun Jan 20 00:00:00 CST 2019, time=2019-01-20, status=1, ipAttribution=)]
    2021-12-29 Mia

    我为什么投了一个月/很长时间都没有消息?

    1

    展开1条回复
  6. [GetPortalCommentsPageByObjectIdResponse(id=2139420, encodeId=97e021394204a, content=投稿投稿,天天发愁, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=192, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ede62857934, createdName=4031828, createdTime=Sat May 27 21:18:24 CST 2023, time=2023-05-27, status=1, ipAttribution=河南省), GetPortalCommentsPageByObjectIdResponse(id=2145327, encodeId=58e0214532e67, content=影响因子51.1分,顶刊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=167, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/Random/55971dc507c93968175ce7cc1e177b372a83869f.jpg, createdBy=f63e4754896, createdName=侠胆医心, createdTime=Thu Jun 29 05:35:33 CST 2023, time=2023-06-29, status=1, ipAttribution=香港), GetPortalCommentsPageByObjectIdResponse(id=504738, encodeId=4b54504e380c, content=审稿速度:1.0 | 投稿命中率:25.0<br>经验分享:楼上投稿,秒拒,可能是研究根本不合适。Lancet Oncology,国内发得多了,吴一龙教授,周彩纯教授,滕皋军教授,他们发了好多,尤其是吴一龙教授和周彩纯教授,几乎成为Lancet Oncology专业户了。一般来说,首先是RCT,但是可以是小规模的(即phase 2),这是可以的。另外,研究应该是很新的话题,如NSCLC,前几年研究EGFR突变,现在呢,一定要做ALK或ROS1之类,另外,研究的传承至关重要,因为发表前,都要附一个system review才可以,你要说明,为什么要开展这个研究,而不是无缘无故做的。我知道medsci协助国内好多大牛发了这个刊物。只要研究合适,似乎并不是这么恐怖的刊物。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=960, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=丁丁, createdTime=Wed Jul 30 18:11:00 CST 2014, time=2014-07-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=579996, encodeId=04305e99960d, content=接受回顾性队列研究吗?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=673, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f0fb2030145, createdName=1e2321c7m65(暂无匿称), createdTime=Sun Nov 17 00:00:00 CST 2019, time=2019-11-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1098625, encodeId=c09310986258e, content=我为什么投了一个月/很长时间都没有消息?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=477, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220301/3a52d3952dde49019f1e000bb5c41d1c/0a0eb7959bb14fcd87745f869bee3c33.jpg, createdBy=46f32239729, createdName=Mia, createdTime=Wed Dec 29 14:52:50 CST 2021, time=2021-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1098626, encodeId=39cd1098626af, content=期刊的审稿时间一般是多久?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=474, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210512/72cbdf927f7647bd84938927488b4795/94fe7f0fd8274d94807c5f3458f0c4e2.jpg, createdBy=9cd75497899, createdName=桑晒麦拉, createdTime=Tue Dec 28 14:52:50 CST 2021, time=2021-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=586501, encodeId=5c2f586501a5, content=最多几个共一啊<span class="quote">lovetcm 2019-06-21 00:00:00 发表:<br>周大大经常发这个期刊</span>, beContent=lovetcm 2019-06-21 00:00:00 发表: 周大大经常发这个期刊, objectType=tool_impact_factor, channel=null, level=null, likeNumber=649, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTKGbxgDxjD7wnYeUQoH0hkCdFqbfXdHY0UL0jBF5ar37Qgo4oA3a9xcLBeadTqricpicm1H9XUJkfnQ/132, createdBy=26d52133758, createdName=陈晓晓晓, createdTime=Fri Mar 13 00:00:00 CST 2020, time=2020-03-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=572694, encodeId=3b7b5e269478, content=周大大经常发这个期刊<span class="quote">153****5167(暂无匿称) 2017-02-02 发表::<br>研究方向:肿瘤;癌症; SCI(2015):26.509 SCI(2014):24.69 是周彩存</span><span class="quote">153****5167(暂无匿称) 2017-02-02 14:14:00 发表:<br>是周彩存</span>, beContent=153****5167(暂无匿称) 2017-02-02 发表:: 研究方向:肿瘤;癌症; SCI(2015):26.509 SCI(2014):24.69 是周彩存, objectType=tool_impact_factor, channel=null, level=null, likeNumber=707, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c4a5105539, createdName=lovetcm, createdTime=Fri Jun 21 00:00:00 CST 2019, time=2019-06-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=572619, encodeId=7bfb5e261999, content=转化研究收的都少,纯基础不收。<span class="quote">sunliang 2019-01-01 发表::<br>这个杂志收基础的文章吗?</span><span class="quote">sunliang 2019-01-01 00:00:00 发表:<br>这个杂志收基础的文章吗?</span>, beContent=sunliang 2019-01-01 发表:: 这个杂志收基础的文章吗?, objectType=tool_impact_factor, channel=null, level=null, likeNumber=750, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c4a5105539, createdName=lovetcm, createdTime=Fri Jun 21 00:00:00 CST 2019, time=2019-06-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=565790, encodeId=c65f565e90f1, content=同学,这个杂志投稿要求能分析一个吗?特别是作者填写,字体大小格式的要求我都找到了<span class="quote">henrypoor 2014-07-30 17:57:00 发表:<br>今天投了一篇,要么就秒拒,要不就赶紧送外审了吧,跪求!!!求祝福!</span>, beContent=henrypoor 2014-07-30 17:57:00 发表: 今天投了一篇,要么就秒拒,要不就赶紧送外审了吧,跪求!!!求祝福!, objectType=tool_impact_factor, channel=null, level=null, likeNumber=742, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/DYAIOgq83eq1fibWvf6gzfzbEVuEZtllrHnhxFxdCXjODby1mSKU0CWzYgFUjtZuufiaSV4ub9l0Ixjjb56SWiaicg/132, createdBy=5e3a2395315, createdName=助手我老婆, createdTime=Sun Jan 20 00:00:00 CST 2019, time=2019-01-20, status=1, ipAttribution=)]
    2021-12-28 桑晒麦拉

    期刊的审稿时间一般是多久?

    1

    展开1条回复
  7. [GetPortalCommentsPageByObjectIdResponse(id=2139420, encodeId=97e021394204a, content=投稿投稿,天天发愁, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=192, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ede62857934, createdName=4031828, createdTime=Sat May 27 21:18:24 CST 2023, time=2023-05-27, status=1, ipAttribution=河南省), GetPortalCommentsPageByObjectIdResponse(id=2145327, encodeId=58e0214532e67, content=影响因子51.1分,顶刊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=167, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/Random/55971dc507c93968175ce7cc1e177b372a83869f.jpg, createdBy=f63e4754896, createdName=侠胆医心, createdTime=Thu Jun 29 05:35:33 CST 2023, time=2023-06-29, status=1, ipAttribution=香港), GetPortalCommentsPageByObjectIdResponse(id=504738, encodeId=4b54504e380c, content=审稿速度:1.0 | 投稿命中率:25.0<br>经验分享:楼上投稿,秒拒,可能是研究根本不合适。Lancet Oncology,国内发得多了,吴一龙教授,周彩纯教授,滕皋军教授,他们发了好多,尤其是吴一龙教授和周彩纯教授,几乎成为Lancet Oncology专业户了。一般来说,首先是RCT,但是可以是小规模的(即phase 2),这是可以的。另外,研究应该是很新的话题,如NSCLC,前几年研究EGFR突变,现在呢,一定要做ALK或ROS1之类,另外,研究的传承至关重要,因为发表前,都要附一个system review才可以,你要说明,为什么要开展这个研究,而不是无缘无故做的。我知道medsci协助国内好多大牛发了这个刊物。只要研究合适,似乎并不是这么恐怖的刊物。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=960, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=丁丁, createdTime=Wed Jul 30 18:11:00 CST 2014, time=2014-07-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=579996, encodeId=04305e99960d, content=接受回顾性队列研究吗?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=673, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f0fb2030145, createdName=1e2321c7m65(暂无匿称), createdTime=Sun Nov 17 00:00:00 CST 2019, time=2019-11-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1098625, encodeId=c09310986258e, content=我为什么投了一个月/很长时间都没有消息?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=477, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220301/3a52d3952dde49019f1e000bb5c41d1c/0a0eb7959bb14fcd87745f869bee3c33.jpg, createdBy=46f32239729, createdName=Mia, createdTime=Wed Dec 29 14:52:50 CST 2021, time=2021-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1098626, encodeId=39cd1098626af, content=期刊的审稿时间一般是多久?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=474, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210512/72cbdf927f7647bd84938927488b4795/94fe7f0fd8274d94807c5f3458f0c4e2.jpg, createdBy=9cd75497899, createdName=桑晒麦拉, createdTime=Tue Dec 28 14:52:50 CST 2021, time=2021-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=586501, encodeId=5c2f586501a5, content=最多几个共一啊<span class="quote">lovetcm 2019-06-21 00:00:00 发表:<br>周大大经常发这个期刊</span>, beContent=lovetcm 2019-06-21 00:00:00 发表: 周大大经常发这个期刊, objectType=tool_impact_factor, channel=null, level=null, likeNumber=649, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTKGbxgDxjD7wnYeUQoH0hkCdFqbfXdHY0UL0jBF5ar37Qgo4oA3a9xcLBeadTqricpicm1H9XUJkfnQ/132, createdBy=26d52133758, createdName=陈晓晓晓, createdTime=Fri Mar 13 00:00:00 CST 2020, time=2020-03-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=572694, encodeId=3b7b5e269478, content=周大大经常发这个期刊<span class="quote">153****5167(暂无匿称) 2017-02-02 发表::<br>研究方向:肿瘤;癌症; SCI(2015):26.509 SCI(2014):24.69 是周彩存</span><span class="quote">153****5167(暂无匿称) 2017-02-02 14:14:00 发表:<br>是周彩存</span>, beContent=153****5167(暂无匿称) 2017-02-02 发表:: 研究方向:肿瘤;癌症; SCI(2015):26.509 SCI(2014):24.69 是周彩存, objectType=tool_impact_factor, channel=null, level=null, likeNumber=707, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c4a5105539, createdName=lovetcm, createdTime=Fri Jun 21 00:00:00 CST 2019, time=2019-06-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=572619, encodeId=7bfb5e261999, content=转化研究收的都少,纯基础不收。<span class="quote">sunliang 2019-01-01 发表::<br>这个杂志收基础的文章吗?</span><span class="quote">sunliang 2019-01-01 00:00:00 发表:<br>这个杂志收基础的文章吗?</span>, beContent=sunliang 2019-01-01 发表:: 这个杂志收基础的文章吗?, objectType=tool_impact_factor, channel=null, level=null, likeNumber=750, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c4a5105539, createdName=lovetcm, createdTime=Fri Jun 21 00:00:00 CST 2019, time=2019-06-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=565790, encodeId=c65f565e90f1, content=同学,这个杂志投稿要求能分析一个吗?特别是作者填写,字体大小格式的要求我都找到了<span class="quote">henrypoor 2014-07-30 17:57:00 发表:<br>今天投了一篇,要么就秒拒,要不就赶紧送外审了吧,跪求!!!求祝福!</span>, beContent=henrypoor 2014-07-30 17:57:00 发表: 今天投了一篇,要么就秒拒,要不就赶紧送外审了吧,跪求!!!求祝福!, objectType=tool_impact_factor, channel=null, level=null, likeNumber=742, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/DYAIOgq83eq1fibWvf6gzfzbEVuEZtllrHnhxFxdCXjODby1mSKU0CWzYgFUjtZuufiaSV4ub9l0Ixjjb56SWiaicg/132, createdBy=5e3a2395315, createdName=助手我老婆, createdTime=Sun Jan 20 00:00:00 CST 2019, time=2019-01-20, status=1, ipAttribution=)]
    2020-03-13 陈晓晓晓

    最多几个共一啊lovetcm 2019-06-21 00:00:00 发表:
    周大大经常发这个期刊

    lovetcm 2019-06-21 00:00:00 发表: 周大大经常发这个期刊

    0

  8. [GetPortalCommentsPageByObjectIdResponse(id=2139420, encodeId=97e021394204a, content=投稿投稿,天天发愁, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=192, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ede62857934, createdName=4031828, createdTime=Sat May 27 21:18:24 CST 2023, time=2023-05-27, status=1, ipAttribution=河南省), GetPortalCommentsPageByObjectIdResponse(id=2145327, encodeId=58e0214532e67, content=影响因子51.1分,顶刊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=167, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/Random/55971dc507c93968175ce7cc1e177b372a83869f.jpg, createdBy=f63e4754896, createdName=侠胆医心, createdTime=Thu Jun 29 05:35:33 CST 2023, time=2023-06-29, status=1, ipAttribution=香港), GetPortalCommentsPageByObjectIdResponse(id=504738, encodeId=4b54504e380c, content=审稿速度:1.0 | 投稿命中率:25.0<br>经验分享:楼上投稿,秒拒,可能是研究根本不合适。Lancet Oncology,国内发得多了,吴一龙教授,周彩纯教授,滕皋军教授,他们发了好多,尤其是吴一龙教授和周彩纯教授,几乎成为Lancet Oncology专业户了。一般来说,首先是RCT,但是可以是小规模的(即phase 2),这是可以的。另外,研究应该是很新的话题,如NSCLC,前几年研究EGFR突变,现在呢,一定要做ALK或ROS1之类,另外,研究的传承至关重要,因为发表前,都要附一个system review才可以,你要说明,为什么要开展这个研究,而不是无缘无故做的。我知道medsci协助国内好多大牛发了这个刊物。只要研究合适,似乎并不是这么恐怖的刊物。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=960, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=丁丁, createdTime=Wed Jul 30 18:11:00 CST 2014, time=2014-07-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=579996, encodeId=04305e99960d, content=接受回顾性队列研究吗?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=673, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f0fb2030145, createdName=1e2321c7m65(暂无匿称), createdTime=Sun Nov 17 00:00:00 CST 2019, time=2019-11-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1098625, encodeId=c09310986258e, content=我为什么投了一个月/很长时间都没有消息?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=477, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220301/3a52d3952dde49019f1e000bb5c41d1c/0a0eb7959bb14fcd87745f869bee3c33.jpg, createdBy=46f32239729, createdName=Mia, createdTime=Wed Dec 29 14:52:50 CST 2021, time=2021-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1098626, encodeId=39cd1098626af, content=期刊的审稿时间一般是多久?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=474, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210512/72cbdf927f7647bd84938927488b4795/94fe7f0fd8274d94807c5f3458f0c4e2.jpg, createdBy=9cd75497899, createdName=桑晒麦拉, createdTime=Tue Dec 28 14:52:50 CST 2021, time=2021-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=586501, encodeId=5c2f586501a5, content=最多几个共一啊<span class="quote">lovetcm 2019-06-21 00:00:00 发表:<br>周大大经常发这个期刊</span>, beContent=lovetcm 2019-06-21 00:00:00 发表: 周大大经常发这个期刊, objectType=tool_impact_factor, channel=null, level=null, likeNumber=649, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTKGbxgDxjD7wnYeUQoH0hkCdFqbfXdHY0UL0jBF5ar37Qgo4oA3a9xcLBeadTqricpicm1H9XUJkfnQ/132, createdBy=26d52133758, createdName=陈晓晓晓, createdTime=Fri Mar 13 00:00:00 CST 2020, time=2020-03-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=572694, encodeId=3b7b5e269478, content=周大大经常发这个期刊<span class="quote">153****5167(暂无匿称) 2017-02-02 发表::<br>研究方向:肿瘤;癌症; SCI(2015):26.509 SCI(2014):24.69 是周彩存</span><span class="quote">153****5167(暂无匿称) 2017-02-02 14:14:00 发表:<br>是周彩存</span>, beContent=153****5167(暂无匿称) 2017-02-02 发表:: 研究方向:肿瘤;癌症; SCI(2015):26.509 SCI(2014):24.69 是周彩存, objectType=tool_impact_factor, channel=null, level=null, likeNumber=707, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c4a5105539, createdName=lovetcm, createdTime=Fri Jun 21 00:00:00 CST 2019, time=2019-06-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=572619, encodeId=7bfb5e261999, content=转化研究收的都少,纯基础不收。<span class="quote">sunliang 2019-01-01 发表::<br>这个杂志收基础的文章吗?</span><span class="quote">sunliang 2019-01-01 00:00:00 发表:<br>这个杂志收基础的文章吗?</span>, beContent=sunliang 2019-01-01 发表:: 这个杂志收基础的文章吗?, objectType=tool_impact_factor, channel=null, level=null, likeNumber=750, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c4a5105539, createdName=lovetcm, createdTime=Fri Jun 21 00:00:00 CST 2019, time=2019-06-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=565790, encodeId=c65f565e90f1, content=同学,这个杂志投稿要求能分析一个吗?特别是作者填写,字体大小格式的要求我都找到了<span class="quote">henrypoor 2014-07-30 17:57:00 发表:<br>今天投了一篇,要么就秒拒,要不就赶紧送外审了吧,跪求!!!求祝福!</span>, beContent=henrypoor 2014-07-30 17:57:00 发表: 今天投了一篇,要么就秒拒,要不就赶紧送外审了吧,跪求!!!求祝福!, objectType=tool_impact_factor, channel=null, level=null, likeNumber=742, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/DYAIOgq83eq1fibWvf6gzfzbEVuEZtllrHnhxFxdCXjODby1mSKU0CWzYgFUjtZuufiaSV4ub9l0Ixjjb56SWiaicg/132, createdBy=5e3a2395315, createdName=助手我老婆, createdTime=Sun Jan 20 00:00:00 CST 2019, time=2019-01-20, status=1, ipAttribution=)]
    2019-06-21 lovetcm

    周大大经常发这个期刊153****5167(暂无匿称) 2017-02-02 发表::
    研究方向:肿瘤;癌症; SCI(2015):26.509 SCI(2014):24.69 是周彩存
    153****5167(暂无匿称) 2017-02-02 14:14:00 发表:
    是周彩存

    153****5167(暂无匿称) 2017-02-02 发表:: 研究方向:肿瘤;癌症; SCI(2015):26.509 SCI(2014):24.69 是周彩存

    0

  9. [GetPortalCommentsPageByObjectIdResponse(id=2139420, encodeId=97e021394204a, content=投稿投稿,天天发愁, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=192, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ede62857934, createdName=4031828, createdTime=Sat May 27 21:18:24 CST 2023, time=2023-05-27, status=1, ipAttribution=河南省), GetPortalCommentsPageByObjectIdResponse(id=2145327, encodeId=58e0214532e67, content=影响因子51.1分,顶刊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=167, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/Random/55971dc507c93968175ce7cc1e177b372a83869f.jpg, createdBy=f63e4754896, createdName=侠胆医心, createdTime=Thu Jun 29 05:35:33 CST 2023, time=2023-06-29, status=1, ipAttribution=香港), GetPortalCommentsPageByObjectIdResponse(id=504738, encodeId=4b54504e380c, content=审稿速度:1.0 | 投稿命中率:25.0<br>经验分享:楼上投稿,秒拒,可能是研究根本不合适。Lancet Oncology,国内发得多了,吴一龙教授,周彩纯教授,滕皋军教授,他们发了好多,尤其是吴一龙教授和周彩纯教授,几乎成为Lancet Oncology专业户了。一般来说,首先是RCT,但是可以是小规模的(即phase 2),这是可以的。另外,研究应该是很新的话题,如NSCLC,前几年研究EGFR突变,现在呢,一定要做ALK或ROS1之类,另外,研究的传承至关重要,因为发表前,都要附一个system review才可以,你要说明,为什么要开展这个研究,而不是无缘无故做的。我知道medsci协助国内好多大牛发了这个刊物。只要研究合适,似乎并不是这么恐怖的刊物。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=960, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=丁丁, createdTime=Wed Jul 30 18:11:00 CST 2014, time=2014-07-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=579996, encodeId=04305e99960d, content=接受回顾性队列研究吗?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=673, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f0fb2030145, createdName=1e2321c7m65(暂无匿称), createdTime=Sun Nov 17 00:00:00 CST 2019, time=2019-11-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1098625, encodeId=c09310986258e, content=我为什么投了一个月/很长时间都没有消息?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=477, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220301/3a52d3952dde49019f1e000bb5c41d1c/0a0eb7959bb14fcd87745f869bee3c33.jpg, createdBy=46f32239729, createdName=Mia, createdTime=Wed Dec 29 14:52:50 CST 2021, time=2021-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1098626, encodeId=39cd1098626af, content=期刊的审稿时间一般是多久?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=474, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210512/72cbdf927f7647bd84938927488b4795/94fe7f0fd8274d94807c5f3458f0c4e2.jpg, createdBy=9cd75497899, createdName=桑晒麦拉, createdTime=Tue Dec 28 14:52:50 CST 2021, time=2021-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=586501, encodeId=5c2f586501a5, content=最多几个共一啊<span class="quote">lovetcm 2019-06-21 00:00:00 发表:<br>周大大经常发这个期刊</span>, beContent=lovetcm 2019-06-21 00:00:00 发表: 周大大经常发这个期刊, objectType=tool_impact_factor, channel=null, level=null, likeNumber=649, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTKGbxgDxjD7wnYeUQoH0hkCdFqbfXdHY0UL0jBF5ar37Qgo4oA3a9xcLBeadTqricpicm1H9XUJkfnQ/132, createdBy=26d52133758, createdName=陈晓晓晓, createdTime=Fri Mar 13 00:00:00 CST 2020, time=2020-03-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=572694, encodeId=3b7b5e269478, content=周大大经常发这个期刊<span class="quote">153****5167(暂无匿称) 2017-02-02 发表::<br>研究方向:肿瘤;癌症; SCI(2015):26.509 SCI(2014):24.69 是周彩存</span><span class="quote">153****5167(暂无匿称) 2017-02-02 14:14:00 发表:<br>是周彩存</span>, beContent=153****5167(暂无匿称) 2017-02-02 发表:: 研究方向:肿瘤;癌症; SCI(2015):26.509 SCI(2014):24.69 是周彩存, objectType=tool_impact_factor, channel=null, level=null, likeNumber=707, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c4a5105539, createdName=lovetcm, createdTime=Fri Jun 21 00:00:00 CST 2019, time=2019-06-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=572619, encodeId=7bfb5e261999, content=转化研究收的都少,纯基础不收。<span class="quote">sunliang 2019-01-01 发表::<br>这个杂志收基础的文章吗?</span><span class="quote">sunliang 2019-01-01 00:00:00 发表:<br>这个杂志收基础的文章吗?</span>, beContent=sunliang 2019-01-01 发表:: 这个杂志收基础的文章吗?, objectType=tool_impact_factor, channel=null, level=null, likeNumber=750, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c4a5105539, createdName=lovetcm, createdTime=Fri Jun 21 00:00:00 CST 2019, time=2019-06-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=565790, encodeId=c65f565e90f1, content=同学,这个杂志投稿要求能分析一个吗?特别是作者填写,字体大小格式的要求我都找到了<span class="quote">henrypoor 2014-07-30 17:57:00 发表:<br>今天投了一篇,要么就秒拒,要不就赶紧送外审了吧,跪求!!!求祝福!</span>, beContent=henrypoor 2014-07-30 17:57:00 发表: 今天投了一篇,要么就秒拒,要不就赶紧送外审了吧,跪求!!!求祝福!, objectType=tool_impact_factor, channel=null, level=null, likeNumber=742, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/DYAIOgq83eq1fibWvf6gzfzbEVuEZtllrHnhxFxdCXjODby1mSKU0CWzYgFUjtZuufiaSV4ub9l0Ixjjb56SWiaicg/132, createdBy=5e3a2395315, createdName=助手我老婆, createdTime=Sun Jan 20 00:00:00 CST 2019, time=2019-01-20, status=1, ipAttribution=)]
    2019-06-21 lovetcm

    转化研究收的都少,纯基础不收。sunliang 2019-01-01 发表::
    这个杂志收基础的文章吗?
    sunliang 2019-01-01 00:00:00 发表:
    这个杂志收基础的文章吗?

    sunliang 2019-01-01 发表:: 这个杂志收基础的文章吗?

    0

  10. [GetPortalCommentsPageByObjectIdResponse(id=2139420, encodeId=97e021394204a, content=投稿投稿,天天发愁, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=192, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ede62857934, createdName=4031828, createdTime=Sat May 27 21:18:24 CST 2023, time=2023-05-27, status=1, ipAttribution=河南省), GetPortalCommentsPageByObjectIdResponse(id=2145327, encodeId=58e0214532e67, content=影响因子51.1分,顶刊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=167, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/Random/55971dc507c93968175ce7cc1e177b372a83869f.jpg, createdBy=f63e4754896, createdName=侠胆医心, createdTime=Thu Jun 29 05:35:33 CST 2023, time=2023-06-29, status=1, ipAttribution=香港), GetPortalCommentsPageByObjectIdResponse(id=504738, encodeId=4b54504e380c, content=审稿速度:1.0 | 投稿命中率:25.0<br>经验分享:楼上投稿,秒拒,可能是研究根本不合适。Lancet Oncology,国内发得多了,吴一龙教授,周彩纯教授,滕皋军教授,他们发了好多,尤其是吴一龙教授和周彩纯教授,几乎成为Lancet Oncology专业户了。一般来说,首先是RCT,但是可以是小规模的(即phase 2),这是可以的。另外,研究应该是很新的话题,如NSCLC,前几年研究EGFR突变,现在呢,一定要做ALK或ROS1之类,另外,研究的传承至关重要,因为发表前,都要附一个system review才可以,你要说明,为什么要开展这个研究,而不是无缘无故做的。我知道medsci协助国内好多大牛发了这个刊物。只要研究合适,似乎并不是这么恐怖的刊物。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=960, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=丁丁, createdTime=Wed Jul 30 18:11:00 CST 2014, time=2014-07-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=579996, encodeId=04305e99960d, content=接受回顾性队列研究吗?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=673, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f0fb2030145, createdName=1e2321c7m65(暂无匿称), createdTime=Sun Nov 17 00:00:00 CST 2019, time=2019-11-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1098625, encodeId=c09310986258e, content=我为什么投了一个月/很长时间都没有消息?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=477, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220301/3a52d3952dde49019f1e000bb5c41d1c/0a0eb7959bb14fcd87745f869bee3c33.jpg, createdBy=46f32239729, createdName=Mia, createdTime=Wed Dec 29 14:52:50 CST 2021, time=2021-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1098626, encodeId=39cd1098626af, content=期刊的审稿时间一般是多久?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=474, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210512/72cbdf927f7647bd84938927488b4795/94fe7f0fd8274d94807c5f3458f0c4e2.jpg, createdBy=9cd75497899, createdName=桑晒麦拉, createdTime=Tue Dec 28 14:52:50 CST 2021, time=2021-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=586501, encodeId=5c2f586501a5, content=最多几个共一啊<span class="quote">lovetcm 2019-06-21 00:00:00 发表:<br>周大大经常发这个期刊</span>, beContent=lovetcm 2019-06-21 00:00:00 发表: 周大大经常发这个期刊, objectType=tool_impact_factor, channel=null, level=null, likeNumber=649, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTKGbxgDxjD7wnYeUQoH0hkCdFqbfXdHY0UL0jBF5ar37Qgo4oA3a9xcLBeadTqricpicm1H9XUJkfnQ/132, createdBy=26d52133758, createdName=陈晓晓晓, createdTime=Fri Mar 13 00:00:00 CST 2020, time=2020-03-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=572694, encodeId=3b7b5e269478, content=周大大经常发这个期刊<span class="quote">153****5167(暂无匿称) 2017-02-02 发表::<br>研究方向:肿瘤;癌症; SCI(2015):26.509 SCI(2014):24.69 是周彩存</span><span class="quote">153****5167(暂无匿称) 2017-02-02 14:14:00 发表:<br>是周彩存</span>, beContent=153****5167(暂无匿称) 2017-02-02 发表:: 研究方向:肿瘤;癌症; SCI(2015):26.509 SCI(2014):24.69 是周彩存, objectType=tool_impact_factor, channel=null, level=null, likeNumber=707, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c4a5105539, createdName=lovetcm, createdTime=Fri Jun 21 00:00:00 CST 2019, time=2019-06-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=572619, encodeId=7bfb5e261999, content=转化研究收的都少,纯基础不收。<span class="quote">sunliang 2019-01-01 发表::<br>这个杂志收基础的文章吗?</span><span class="quote">sunliang 2019-01-01 00:00:00 发表:<br>这个杂志收基础的文章吗?</span>, beContent=sunliang 2019-01-01 发表:: 这个杂志收基础的文章吗?, objectType=tool_impact_factor, channel=null, level=null, likeNumber=750, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c4a5105539, createdName=lovetcm, createdTime=Fri Jun 21 00:00:00 CST 2019, time=2019-06-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=565790, encodeId=c65f565e90f1, content=同学,这个杂志投稿要求能分析一个吗?特别是作者填写,字体大小格式的要求我都找到了<span class="quote">henrypoor 2014-07-30 17:57:00 发表:<br>今天投了一篇,要么就秒拒,要不就赶紧送外审了吧,跪求!!!求祝福!</span>, beContent=henrypoor 2014-07-30 17:57:00 发表: 今天投了一篇,要么就秒拒,要不就赶紧送外审了吧,跪求!!!求祝福!, objectType=tool_impact_factor, channel=null, level=null, likeNumber=742, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/DYAIOgq83eq1fibWvf6gzfzbEVuEZtllrHnhxFxdCXjODby1mSKU0CWzYgFUjtZuufiaSV4ub9l0Ixjjb56SWiaicg/132, createdBy=5e3a2395315, createdName=助手我老婆, createdTime=Sun Jan 20 00:00:00 CST 2019, time=2019-01-20, status=1, ipAttribution=)]
    2019-01-20 助手我老婆

    同学,这个杂志投稿要求能分析一个吗?特别是作者填写,字体大小格式的要求我都找到了henrypoor 2014-07-30 17:57:00 发表:
    今天投了一篇,要么就秒拒,要不就赶紧送外审了吧,跪求!!!求祝福!

    henrypoor 2014-07-30 17:57:00 发表: 今天投了一篇,要么就秒拒,要不就赶紧送外审了吧,跪求!!!求祝福!

    0

共36条页码: 1/4页10条/页
分享您的投稿经验,提升MI经验值,获取更多积分